Baxter (NYSE:BAX) said today that it inked a partnership deal with Biomérieux looking to develop biomarkers to identify acute kidney injury.
The partnership was announced at the International Symposium on Intensive Care and Emergency Medicine, Deerfield, Ill.-based Baxter said.
Both companies said they hope to develop the biomarkers to help rapidly identify and inform treatment of acute kidney injuries, which can lead to death if untreated.
“We’re committed to improving outcomes for critically ill patients across the continuum of care, which includes identifying opportunities to diagnose AKI earlier so a patient can receive the best therapy. By working with the team at Biomérieux, we’ll be able to combine their expertise in diagnostics with our experience in bringing the latest medical advancements to the ICU,” Baxter acute therapies biz GM Reaz Rasul said in a prepared statement.
“As a leader in pioneering diagnostic solutions, we’re looking forward to collaborating with Baxter to address the important challenges in critical care medicine such as AKI. In order to accomplish this, the team at the recently-acquired Astute Medical is committed to the development of additional high medical value biomarkers for improved patient care,” Biomérieux chief medical officer Mark Miller said in a press release.
In January, Baxter said that it acquired healthcare software developer True Process.
